Daily low-dose aspirin for a minimum of 5 years appears to have more
benefits than harms in terms of cancer prevention.

The review found reduced cancer incidence and mortality at doses
between 75 and 325 mg per day, starting between ages 50 and 65, with
longer duration of use appearing to confer the greatest benefits.

The researchers found substantial benefit in terms of colorectal,
esophageal, and gastric cancer incidence and mortality. Reductions in
breast, lung, and prostate cancers were more modest.

As expected, aspirin use was associated with increased risk for
bleeding events, but the cancer-prevention benefits outweighed this
risk.

-Annals of Oncology